Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics has announced a delay in lodging its full year financial statements, owing to a pending capital raising announcement anticipated to complete by 18 October 2024. The Australian clinical-stage cell therapy company is known for its innovative cancer treatments and has a diverse portfolio, including therapies currently in clinical trials. Chimeric is committed to the discovery, development, and commercialization of groundbreaking cell therapies aimed at curing cancer.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.